GlassScriptPhysician profile
Emily Blumenthal
NPI 1396368999
$3,564.04
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,263 · 2022: $1,777 · 2023: $524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $524.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $523.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,068.27 | 2021-2023 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $571.70 | 2021-2023 | |
| Eisai INC. | $339.52 | 2021-2022 | |
| Abbvie INC. | $287.73 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $242.36 | 2021-2023 | Farxiga |
| Lilly USA, LLC | $170.85 | 2021-2022 | |
| Dexcom, INC. | $157.62 | 2022-2023 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $125.04 | 2022-2023 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $116.24 | 2021-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.60 | 2022-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $67.42 | 2022-2023 | Belsomra |
| Amgen INC. | $59.33 | 2022-2023 | Repatha, Otezla |
| Pfizer INC. | $49.28 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $37.80 | 2021 | |
| Phadia US INC. | $28.84 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $28.44 | 2023 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $25.94 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $25.81 | 2023 | Eliquis |
| Otsuka America Pharmaceutical, INC. | $24.45 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.72 | 2023 | Trulance |
| Idorsia Pharmaceuticals US INC | $17.88 | 2023 | Quviviq |
| Vivus LLC | $12.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Blumenthal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.